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DBackground: Although the frequency of biological valve use in treating aortic valve disease is increasing, the
critical limiting factor, ‘‘structural deterioration,’’ remains unresolved. Analysis of long-term outcomes after
implantation of cryopreserved aortic allografts will yield further information related to the durability of the
aortic allograft, possibly suggesting mechanisms underlying or strategies to prevent or treat the structural
deterioration of biological valve substitutes.
Methods: A total of 840 cryopreserved aortic allografts implanted in the last 35 years were reviewed with
clinical follow-up completed in 99% of the consecutive series. By June 2010, 285 implanted allografts had
been surgically explanted, 288 patients died before allograft removal, and 267 patients are under continued
follow-up.
Results: Cryopreserved aortic allografts were durable for more than 15 years in the middle-aged and older
patient population. The estimated median time until structural deterioration was 20 years post-implantation,
and 2 allografts have been functioning well for more than 30 years. Structural deterioration was independently
related to the young age of the recipient, elderly age of the donor, severe obesity in the recipient, history of blood
transfusion in the recipient, and full-root implantation technique. Infection of the implanted allograft neces-
sitating reintervention rarely occurred. Reintervention for the allograft demonstrated 2% in-hospital mortality.
Conclusions: Cryopreserved aortic allografts were durable for more than 15 years. Structural deterioration of
aortic allografts was related to multiple factors. The age of the recipient and the donor, obesity and blood
transfusion history of the recipient, and implantation technique were identified as the most important factors
contributing to allograft failure. (J Thorac Cardiovasc Surg 2014;148:65-72)Supplemental material is available online.
Severe aortic valve disease is one of the major causes of
cardiac death worldwide, whereas aortic valve replacement
using a mechanical or biological valve substitute remains
the gold standard treatment.1 Biological valve substitutes
have a number of clinical advantages over mechanical
valves, including nonrequirement of anticoagulant therapy
and absence of noise. However, structural deterioration
remains the ‘‘Achilles’ heel’’ of biologic prostheses because
of the requirement for often complex reoperation and the
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The Journal of Thoracic and CStructural deterioration of biological valve substitutes
consistently shows atherosclerosis-like inflammatory
changes regardless of valve substitute types,3,4 indicating
that common mechanisms or processes contribute to
progressive valve failure, although factors related to the
structural deterioration are not fully understood.
The aortic allograft is one of the alternative biological
valve substitutes used in clinical practice over the last
50 years,5,6 although the use of the aortic allograft is not
widely accepted because of the limited supply, variable
implantation techniques contributing to uncertainty of the
function, durability of the valve,7 and prospect of a
challenging reintervention.8 At The Prince Charles Hospi-
tal, the cryopreserved aortic allograft has been implanted
in a variety of patients as a treatment for severe aortic valve
disease and has been the primary choice of valve substitute
since 1975 when Queensland Heart Valve Bank was
established to collect, prepare, store, and catalogue the
allograft for implantation.5 We explored the long-term
outcomes of all patients after implantation of this single
valve substitute, the ‘‘aortic allograft.’’ The aim was to
identify factors influencing allograft durability and to
explore putative mechanisms that may help to prevent or
treat structural deterioration of biological valve substitutes.ardiovascular Surgery c Volume 148, Number 1 65
Abbreviation and Acronym
AS ¼ aortic stenosis
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DMATERIALS AND METHODS
Cohort and Data Collection
The prospective database contained 7973 aortic valve and root
replacement surgeries performed in The Prince Charles Hospital between
January 1975 and December 2008. The cryopreserved aortic allograft
was used as the valve substitute in 852 cases (11%). Clinical progress of
the patients was followed up with annual visits to the institutional or local
physicians. Medical charts and referral letters, including serial echocardio-
graphic studies, were reviewed to obtain the data, which were further
supplemented by telephone interviews of patients under the care of distant
physicians. Data collection was performed between January 2010 and June
2010. Mortality data also were gathered by request to the National Death
Registry in December 2010. The study was approved by the institutional
ethics committee (reference number HREC/09/QPCH/152).
Study End Points
A total of 285 allografts were surgically explanted by June 2010, and
288 patients died before removal of their aortic allograft, with explant
and death defined as primary end points of this study. A further 267 patients
who did not reach the primary end points were under continued follow-up
until June 2010, and 12 patients were not contactable for or refused clinical
assessment as of June 2010. Therefore, clinical follow-up was completed in
98.6% of total, consecutive cryopreserved aortic allografts in The Prince
Charles Hospital. This gives an overall total of 840 allografts retrospec-
tively studied from January 1975 to June 2010. Secondary end points
assessed included other adverse cardiac events, such as structural/nonstruc-
tural failure and infection of the implanted allograft, which were defined
according to the guideline.9
Treatment Strategies and Surgical Techniques
Surgical strategies in The Prince Charles Hospital to treat severe aortic
valve disease have been consistently to replace the aortic valve using a
mechanical or biological valve substitute. However, there were several
evolutions through the study period. First, choice of the valve substitute
has been modified according to the availability and the concerns related
to the durability of the valve substitutes.5 Until the early 1990s, the aortic
allograft was the primary choice of valve substitute in any patient whose
aortic annular anatomy was suitable for allograft implantation, regardless
of the patient’s age, although the use of the allograft was deferred in a
number of patients because of limited availability or inadequate anatomy.
In the mid to late 1990s, the use of the allograft was gradually limited by
operating surgeons who were concerned about allograft durability. Since
2000, the aortic allograft has been used only in neonates, infants, small
children, or patients with severe infective abscess in the aortic annulus.
Second, the pattern of aortic valve pathologies has gradually altered
over the 3 decades in line with changes in the patient population.
Rheumatic valvular disease was predominant in the first decade of the
study, whereas endocarditis predominated in the last decade. Therefore,
the characteristics and background of the cohort are substantially different
among the eras of surgery (Table 1). Finally, surgical techniques to implant
the allograft have been markedly modified over the 3 decades (Table 2).
The subcoronary implantation technique was the surgical strategy in the
first decade, when the allograft was sized 3 mm less than the valve annulus
dimension. In the second decade, operating surgeons applied the full-root
implantation technique, implanting an allograft sized the same as the native
valve annulus dimension. This was done to achieve more consistent
technical results to match congenital pathology with asymmetric annulus
morphologies compared with the subcoronary technique, in which there66 The Journal of Thoracic and Cardiovascular Surgeis often difficulty in achieving perfect cusp alignment, resulting in some
degree of incompetency. In addition, the intellect at this stage was to foster
allograft integrity by maintaining the allograft valve in its natural position.
In the process of this change, the inclusion-cylinder technique also was
used, albeit briefly. Selection of the allograft was primarily dependent on
the size of the native annulus, which was intraoperatively measured.
No consistent attempt was made to match age, sex, or blood group.
No patients received immunosuppressive medications post-allograft
implantation. Allograft infection was essentially treated in the same
clinical manner as native aortic valve endocarditis, for which antibiotics
were the first choice of treatment unless septic thromboembolism or large
vegetation on the allograft was evident.5 Reintervention for the allograft
was indicated when the implanted allograft presented with structural/
nonstructural deterioration or medically uncontrollable infection, or the
heart developed end-stage heart failure requiring cardiac transplantation.
Statistical Analyses
Continuous variables are presented as mean  standard deviation or
median (interquartile range). Categoric variables are shown as the
percentage of the sample. Comparisons between the groups divided into
the era of surgery were performed using 1-way analysis of variance
followed by Dunn’s multiple comparison test (Tables 1 and 2). Predictors
of in-hospital mortality were identified using multivariate logistic
regression, where potential predictors were those showing a P value less
than .10 in a single variable analysis (Table E1). Survival, freedom from
structural deterioration, and freedom from allograft infection were
estimated using the Kaplan–Meier method (Figures 1, 2, and E1).
Predictors of survival and structural deterioration were identified using a
Cox proportional hazard model (Table 3). The potential predictors in a
multivariate Cox proportional hazard model were those with a P value
less than .10 in a single variable model (Tables E2 and E3). Statistical
analysis was performed with GraphPad Prism 4 (GraphPad Software Inc,
La Jolla, Calif) and StatView-J 5.0 (SAS Institute Inc, Cary, NC).
RESULTS
In-Hospital Outcomes of Aortic Allograft
Implantation
In-hospital mortality after aortic allograft implantation
occurred in 21 patients (2.5%), including deaths in the
operating room in 5 patients. A further 11 patients showed
evidence of ventricular problems, with 9 having global
dysfunction and 2 having tachyarrhythmia. Cerebrovas-
cular accidents occurred in 3 patients, and overwhelming
sepsis occurred in 2 patients. Risk factors of in-hospital
mortality were older age, hypertension, smoking history,
and New York Heart Association functional class III or IV
(Table E1).
Implantation of Aortic Allograft to Treat Active
Infective Endocarditis
Aortic allografts were implanted in 101 patients to treat
active endocarditis. Sixty-seven patients (66%) had a native
aortic valve endocarditis, and 34 patients (34%) had an
infection of a previously implanted valve substitute, such
as a prosthesis in 23 patients and an allograft in 11 patients.
The subcoronary technique was used in 33 cases of native
endocarditis and 5 cases of valve substitute infection.
In contrast, the full-root technique was used in 33 cases
of native endocarditis and 29 cases of valve substitutery c July 2014
TABLE 1. Background and characteristics of patients
1975-1984
(n ¼ 147)
1985-1995
(n ¼ 541)
1996-2008
(n ¼ 152)
Age (y; median, range) 58 (3-77) 49 (1-80)* 40 (0-75)*,y
Age (y)
0-19 7 (5%) 39 (7%) 15 (10%)
20-39 19 (13%) 142 (26%) 61 (40%)
40-59 53 (36%) 196 (36%) 64 (42%)
60-81 68 (46%) 164 (30%) 12 (8%)
Gender (male) 75 (51%) 368 (68%)* 119 (78%)*
BMI>35 kg/m2 1 (1%) 13 (2%) 11 (7%)*,y
Smoking history 38 (26%) 59 (11%) 29 (19%)*
Hypertension 73 (50%) 219 (40%) 47 (31%)*
Dyslipidemia 13 (9%) 113 (21%)* 25 (16%)
Diabetes 11 (7%) 45 (8%) 8 (5%)
Renal failure 5 (3%) 26 (5%) 11 (7%)
Preoperative AI * *,y
Nil or trivial 75 (51%) 184 (34%) 27 (18%)
Mild 29 (20%) 64 (12%) 14 (9%)
Moderate 13 (9%) 56 (10%) 26 (17%)
Severe 30 (20%) 237 (44%) 85 (56%)
Surgical indication * *,y
Isolated AS 100 (68%) 248 (46%) 40 (26%)
Isolated AI 28 (19%) 217 (40%) 91 (60%)
Mixed AS and AI 19 (13%) 68 (13%) 19 (13%)
Thoracic aortic aneurysm 0 8 (1%) 2 (1%)
Cause *
Degenerative 27 (18%) 154 (28%) 28 (18%)
Congenital 83 (56%) 327 (60%) 109 (72%)
Rheumatic 37 (25%) 60 (11%) 15 (10%)
Endocarditis * *,y
None 143 (97%) 478 (88%) 108 (71%)
Active 4 (3%) 54 (10%) 43 (28%)
Treated 0 9 (2%) 1 (1%)
Preoperative LVEF<40% 10 (7%) 70 (13%) 8 (5%)y
History of blood transfusion 13 (9%) 80 (15%) 53 (35%)*,y
Previous intervention *,y
None 140 (95%) 472 (87%) 100 (66%)
Allograft 2 (1%) 9 (2%) 20 (13%)
Mechanical or biological
prosthesis
1 (1%) 30 (6%) 17 (11%)
Aortic valve repair 4 (3%) 26 (5%) 13 (9%)
Coarctation repair 0 4 (1%) 2 (1%)
NYHA functional class * *
I 1 (1%) 72 (13%) 23 (15%)
II 65 (44%) 365 (67%) 99 (65%)
III 68 (46%) 89 (16%) 24 (16%)
IV 13 (9%) 15 (3%) 6 (39%)
AI, Aortic insufficiency; AS, aortic stenosis; BMI, body mass index; LVEF, left ven-
tricular ejection fraction; NYHA, New York Heart Association. *P< .05 versus
1975-1984. yP<.05 versus 1985-1995.
TABLE 2. Operative and perioperative characteristic of patients by
era of surgery
1975-1985
(n ¼ 147)
1986-1995
(n ¼ 541)
1996-2008
(n ¼ 152)
In-hospital death 9 (6%) 10 (2%)* 2 (1%)*
Allograft implantation
technique
* *,y
Subcoronary 147 (100%) 290 (54%) 3 (2%)
Full-root 0 217 (40%) 148 (97%)
Inclusion-cylinder 0 34 (6%) 1 (1%)
Concomitant coronary artery
bypass graft
21 (14%) 51 (9%) 5 (3%)*
Concomitant mitral valve 24 (16%) 39 (7%)* 11 (7%)*
Concomitant ascending aorta 2 (1%) 62 (11%)* 12 (8%)
Native aortic annulus
(mm; median, range)
26 (19-30) 26 (16-40) 25 (14-40)y
Native aortic annulus>28 mm 10 (7%) 125 (23%)* 21 (14%)y
Native aortic annulus<21 mm 4 (3%) 37 (7%) 16 (11%)*
Nil aortic annular calcification 28 (19%) 206 (38%)* 75 (49%)y
Severe aortic annular
calcification
38 (26%) 90 (17%) 16 (11%)*
Donor age (y; median, range) 20 (5-50) 29 (8-58)* 40 (2-59)*,y
Donor age>50 y 1 (1%) 51 (9%) 38 (25%)y
Donor annulus (mm; median,
range)
22 (15-25) 24 (17-32)* 25 (15-30)*
Gender mismatch 70 (48%) 368 (68%)* 73 (48%)y
Blood group mismatch 83 (56%) 338 (62%) 86 (57%)
Rh antigen mismatch 55 (37%) 154 (28%) 26 (17%)*
Annular size mismatch (>5 mm) 18 (12%) 39 (7%) 9 (6%)
*P<.05 versus 1975-1984. yP<.05 versus 1985-1995.
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in 1 case of native endocarditis. Thus, 85% of valve
substitute infection was treated by the full-root technique.
As a result, 2 patients with native endocarditis and 2 patients
with valve substitute infection died in the hospital.
One patient with native endocarditis presented with sutureThe Journal of Thoracic and Cline dehiscence, necessitating reintervention 8 days after
allograft implantation.
Survival After Aortic Allograft Implantation
Of the 840 patients, 288 (34%) died without redo
allograft surgery. Causes of late death were (1) allograft-
related cardiac arrests in 15 patients (5%), (2) other cardiac
events in 44 patients (15%), (3) sudden, unexpected in 49
patients (17%), (4) noncardiac events in 134 patients
(47%), and (5) unknown in 24 patients (8%). Estimated
median survival post-allograft implantation was 11 years
if age was 0 to 19 years at implantation, 24 years for those
aged 20 to 39 years, 22 years for those aged 40 to 59 years,
and 14 years for those aged 60 to 81 years (Figure 1).
Predictive factors of death were elderly age at surgery,
preoperative serum creatinine greater than 150 mmol/L,
preoperative New York Heart Association functional class
III or IV, preoperative left ventricular ejection fraction
less than 40%, and concomitant mitral valve surgery.
Year of surgery, cause, or implantation method were not
predictors of death (Tables E2 and E3).
Structural Deterioration of Aortic Allograft
Among the 840 patients, 266 (32%) developed structural
deterioration with an estimated median time of 20 yearsardiovascular Surgery c Volume 148, Number 1 67
FIGURE 1. Kaplan–Meier plot of survival after allograft implantation by (A) age at operation (0-19 vs 20-39 years vs 40-59 vs 60-81 years);
(B) year of surgery (1975-1984 vs 1985-1995 vs 1996-2008); (C) cause (congenital vs degenerative vs rheumatic); and (D) implantation techniques
(subcoronary vs full-root vs inclusion-cylinder).
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‘‘any change in function of an operated valve resulting
from an intrinsic abnormality of the valve that causes
stenosis or regurgitation exclusive of thrombosis or
infection.’’9 This definition was confirmed by the medical
chart, which described the symptoms, physical examina-
tions, echocardiography report, and reoperation record.
In the patients experiencing structural deterioration, 236
allografts (89%) were surgically explanted, and 13 patients
(5%) are listed for reintervention. Fifteen patients (6%)
died, and 2 patients (1%) had reintervention deferred
because of comorbidities. Of the explants, 178 allografts
were explanted in The Prince Charles Hospital. The
pathology noted included a rupture of 1 or more leaflets
in 123 patients (71%), poor leaflet coaptation in 5 patients
(3%), and heavily calcified leaflets in 46 patients (26%). Of
note, allografts in 2 patients have been functioning well for
more than 30 years. These 2 patients were aged 28 years and
35 years at the time of surgery, both having a congenital
aortic stenosis (AS), and underwent subcoronary implanta-
tion of the allograft retrieved from 20-year-old and 33-year-
old donors, respectively. Both patients have not presented
with any cardiovascular risk factors.
Structural deterioration was significantly related to the
patient’s age at operation (Figure 2). Estimated median
time until structural deterioration was 11 years for those
aged 10 to 19 years, 18 years for those aged 20 to 39 years,68 The Journal of Thoracic and Cardiovascular Surge19 years for those aged 40 to 59 years, and 21 years for
those aged 60 to 81 years (P< .0001). The full-root and
inclusion-cylinder implantation techniques had shorter
times free from structural deterioration compared with the
subcoronary technique (P< .001). The estimated median
time until structural deterioration was 21 years after
the subcoronary technique, 16 years after the full-root
technique, and 18 years after the inclusion-cylinder
technique. Results from the Cox model found risk factors
influencing valve durability were elderly age, body mass
index greater than 35 kg/m2, history of blood transfusion,
donor aged more than 50 years, and the full-root technique
(Tables 3 and E3). Blood group mismatch was not a
significant risk factor for structural deterioration.
Echocardiographic studies for the 254 patients whose
implanted allografts failed to show structural deterioration
at the latest clinical follow-up identified moderate-severe
AS in 3 patients, moderate AS in 12 patients, moderate-
severe aortic incompetency in 11 patients, and moderate
aortic incompetency in 47 patients; the median period to
the echocardiographic study was 13 years, ranging from
169 days to 30 years. The other 181 patients showed mild
or less stenosis or incompetency in the allograft.
Nonstructural Allograft Deterioration
Among the patients, 19 (2%) developed nonstructural
deterioration, which was related to dehiscence of the suturery c July 2014
FIGURE 2. Kaplan–Meier plot of actuarial freedom of structural deterioration of all the allografts by (A) age at operation (0-19 vs 20-39 years vs 40-59 vs
60-81 years); (C) year of surgery (1975-1984 vs 1985-1995 vs 1996-2008); (D) cause (congenital vs degenerative vs rheumatic); (E) implantation techniques
(subcoronary vs full-root vs inclusion-cylinder). B, Kaplan–Meier plot of cumulative hazard of reoperation of the allograft by age at operation (0-19 vs 20-39
years vs 40-59 vs 60-81 years). F, Kaplan–Meier plot of actuarial freedom of structural deterioration of subcoronary implanted allografts by age at operation
(0-19 vs 20-39 years vs 40-59 vs 60-81 years).
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TABLE 3. Predictors of structural deterioration of allograft using the
Cox multivariate model
HR 95% CI P value
Year of surgery 0.99 0.96-1.01 .303
Elderly age 1.05 1.04-1.06 <.001
Smoking history 1.10 0.81-1.50 .531
Hypertension 0.98 0.75-1.29 .895
Diabetes 1.08 0.71-1.63 .722
Preoperative serum creatinine>150 mmol/L 2.64 1.72-4.04 <.001
NYHA functional class III or IV 1.34 1.01-1.89 .045
Congenital cause 0.66 0.44-1.00 .050
Nil or trivial AI 1.06 0.71-1.59 .763
Preoperative LVEF<40% 1.86 1.27-2.72 .001
Nil aortic valve calcification 0.89 0.61-1.28 .519
Aortic annulus>28 mm 0.80 0.54-1.19 .270
Full-root technique 1.12 0.77-1.64 .548
Concomitant aortic surgery 0.72 0.38-1.36 .314
Concomitant mitral valve surgery 2.02 1.29-3.14 .002
AI, Aortic insufficiency; CI, confidence interval; HR, hazard ratio; LVEF, left ventri-
cular ejection fraction; NYHA, New York Heart Association.
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4, with the median period being 11 months ranging from
2 days to 18 years post-implantation. In this group, 13 allo-
grafts were implanted with the subcoronary method (68%),
5 allografts were implanted with the full-root method
(26%), and 1 allograft was implanted with the inclusion-
cylinder method (5%).
New or Recurrent Infection of Implanted Allograft
Early infection of the implanted allograft (within 30 days
post-implantation) developed in 2 patients (0.2%); of them,
1 patient developed septic shock related to allograft
infection and eventually died at 18 days post-allograft
implantation, and 1 patient developed staphylococcus
infection in the allograft 14 days post-implantation and
successfully underwent infected allograft explant and root
replacement at 16 days. These 2 patients did not have a
history of infective endocarditis preoperatively. On the
other hand, 46 patients (5.5%) developed late infection
with a median time of 5 years ranging from 4 months to
16 years post-allograft implantation. In this group, 7 died
before reintervention, 27 allografts were explanted during
the acute phase of allograft infection, and 12 infected
allografts (25%) were successfully treated medically.
Freedom from allograft infection at 10 years post-
implantation was 88% in patients who had active endo-
carditis at the time of allograft implantation (n ¼ 101)
and 95% in patients without a history of endocarditis
(n ¼ 729) (Figure E1).
Reintervention After Aortic Allograft Implantation
A total of 285 allografts (34%) were surgically
explanted, and 216 (76%) were performed at The Prince
Charles Hospital. Median time to reintervention was70 The Journal of Thoracic and Cardiovascular Surge12 years after the subcoronary method, 9 years after the
full-root method, and 10 years after the inclusion-cylinder
method. Surgical indications for the reintervention were
structural deterioration in 169 patients, nonstructural
deterioration in 19 patients, infection in 25 patients, and
end-stage heart failure leading to cardiac transplantation
in 3 patients. Of the 116 patients who had an allograft
implanted with the subcoronary method, reintervention
was achieved by replacing the aortic valve in only
89 (77%), replacing the aortic root in 24 (21%), and cardiac
transplantation in 3 (3%). In contrast, of 91 patients who
had an allograft implanted with the full-root method,
reintervention was performed by replacing the allograft
aortic valve in 23 (25%) and replacing the entire allograft
root in 68 (75%). In-hospital mortality after reintervention
occurred in 4 patients (2%), due to global myocardial
dysfunction in 3 patients and persistent sepsis in 1 patient.
Other in-hospital adverse cardiac events included cerebral
infarction in 1 patient and persistent ventricular tachycardia
in 1 patient.
DISCUSSION
This study documents the long-term outcomes after
aortic allograft implantation for severe aortic valve disease,
where 68% of 840 patients reached the primary end points
of death or surgical explant of the implanted allograft.
Most of the aortic allografts structurally deteriorated to
predominantly produce valve incompetence over the
2 decades, significantly related to the young age of the
recipient, elderly age of the donor, severe obesity in the
recipient, history of blood transfusion, and full-root
implantation. Nonstructural deterioration predominantly
occurred after subcoronary implantation. Infection of the
implanted allograft rarely occurred, whereas use of the
allograft for active endocarditis was associated with a
favorable outcome. Finally, in-hospital mortality for
reintervention of the failed allograft was 2%, which is
acceptable when compared with redo aortic valve replace-
ment surgery.
The aortic allograft is hemodynamically an ideal valve
substitute to replace a diseased aortic valve/root, because
it consists of the same physiologic structure as the native
aortic valve/root, which is known to perform extremely
sophisticated functions.10 Among a variety of reported
allograft preparation methods, including fresh or homovital
methods, The Queensland Heart Valve Bank established
cryopreservation because it was shown to preserve viable
valvular interstitial cells,11 which play a major role in
maintaining the normal valvular functions. However, it
has been suggested that the valvular interstitial cells in the
allograft might gradually develop necrosis or apoptosis,
possibly by the host immune response,4,12,13 leading
to structural deterioration. However, our findings that
allografts rarely deteriorate within 5 years and that half ofry c July 2014
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that these immune/inflammatory reactions are slow
despite the absence of immunosuppressive drugs.
Contemporary biological prosthetic valves, whose leaflets
were processed from glutaraldehyde-treated xeno-tissue,
have been shown to structurally deteriorate over 10 to
20 years,14-16 essentially because of an atherosclerosis-
like inflammatory process. Given that biological prosthetic
valves were implanted only in patients aged more than 60
years in these reports, the durability of the allografts, which
was 20 years post-implantation on average in this study, is
not shorter than that of contemporary biological prosthesis.
Of note, patient–prosthesis mismatch, which is reportedly
a cause of valve failure of biological prosthesis,17 rarely
occurs post-allograft implantation,18 suggesting an advan-
tage of the allograft over the biological prosthesis.
In addition to the previously reported risk factors, such as
young age of the recipient or elderly age of the donor,
this study identified that body mass index greater than
35 kg/m2 and history of blood transfusion also were
independent predictors of structural deterioration. Multiple
inflammatory cytokines, which are systemically upregu-
lated in severely obese patients, might lead to acceleration
of the inflammation in the allograft.19 Blood transfusion,
which may be seen as a ‘‘liquid organ transplant,’’ activates
the immune system to exacerbate the immune and inflam-
matory reaction against the allograft.20 Of note, 2 allografts
have been functioning well for more than 30 years. Both
patients sustained a healthy lifestyle during the follow-up,
as seen in the similar case reported by El-Hamamsy and
colleagues.21 This may suggest that the chronic inflamma-
tory state associated with cardiovascular risk factors accele-
rates the structural deterioration of the allograft. Education
of recipients regarding the benefits of a healthy lifestyle
may be useful in an attempt to reduce the progression of
structural deterioration of the biological valve substitute.
This study also suggests that subcoronary implantation is
associated with reduced structural allograft deterioration
when compared with full-root implantation. In contrast,
previous reports, including one from our institution, showed
that full-root implantation demonstrated durability similar to
or greater than that observed for subcoronary implanta-
tion.5,22,23 One should consider several reasons for such a
contrary finding. First, previous reports analyzed risk
factors for reintervention, whereas this study analyzed each
pathology to clarify risk factors. Structural deterioration,
which is the most dominant pathology leading to morbidity
and mortality, developed less frequently after subcoronary
implantation than after full-root implantation, whereas
nonstructural deterioration rarely but predominantly
occurred after subcoronary implantation. Second, aortic allo-
grafts in this studywere cryopreserved, whereas allografts in
other studies were prepared in a different fashion, such as the
homovital method,6 or in an often inconsistent manner.22The Journal of Thoracic and CThird, differences in follow-up period or analysis methods
also may contribute to the contrary findings. No pathologic
reason can be proffered to explain the finding that
subcoronary implantation was more durable than full-root
implantation, but one could postulate that the full-root tech-
nique leaves a larger amount of allograft wall tissues, which
may therefore induce a heightened immune/inflammatory
response compared with the subcoronary technique. In
addition, the allograft implanted with a subcoronary
technique, which is supported by the native aortic annulus
that dynamically connects to ventricular motion,10 could
confront less mechanical stress than the allograft implanted
with a full-root technique. However, there is difficulty
in achieving perfect cusp alignment in the subcoronary
technique, often resulting in some degree of incompetency
without experience.
One of the most important indications for the use of the
aortic allograft is currently active endocarditis involving
the aortic root or annulus.24 Predominant use of the
full-root implantation procedure, which excludes extensive
infective tissue in the pericardial space, may be a significant
factor in producing favorable short- and long-term
outcomes in this study. In addition, infection involving the
implanted allograft, which included minimal prosthetic
material, was medically treatable, similar to the native valve
infection as shown in this study. It may thus be warranted
that the aortic allograft is an ideal valve substitute in
severe, acute aortic valve endocarditis, native or prosthetic.
Moreover, the aortic allograft would be a good valve
substitute for rheumatic valve disease, especially where
there will be a scarred annulus and symmetric root.
Therefore, the aortic allograft would have significant
advantages over prosthetic material in geographic areas
where medical support is not optimal when attempting
to treat local or systemic infection, or where medical
follow-up of the patients cannot be guaranteed.
Reintervention post-aortic allograft implantation is repor-
tedly a surgical challenge because of severe calcific adhesion
in the allograft and the surrounding tissue, including the
coronary ostia.8 However, in-hospital mortality of reinter-
vention was only 2% in this study. The surgical strategy
for which redo root replacement is essential after full-root
implantation would consistently provide excellent results.25
We believe that redo surgery after allograft implantation by
the full-root technique is not well suited to transcatheter
aortic valve replacement as an option, because the coronary
ostia do not sit high after allograft implantation, although
Khalpey and colleagues26 recently reported that the valve-
in-valve proceduremay be a good option for allograft failure.
Study Limitations
Some limitations in this study are related to the
retrospective nature. The valve pathologies, the patient cha-
racteristics, and the implantation technique were markedlyardiovascular Surgery c Volume 148, Number 1 71
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to care’’ for evolving allograft regurgitation markedly
changed over the study period. In the era of ‘‘subcoronary’’
implantation, the intent to treat moderate or less allograft
regurgitation was to observe because it was considered to
be stable,5 whereas in the ‘‘full-root’’ era, the intent to treat
allograft regurgitation was more aggressive, because the
redo surgery after full-root implantation was complex,
requiring sufficient patient and cardiac reserve to obtain
satisfactory perioperative mortalities. Most important,
evolution of the medical treatments, such as b-blockers,
angiotensin-converting enzyme inhibitors, and angiotensin
II receptor blockers, during the study period would have
substantial effects on the patient outcome, in particular, on
survival. Another limitation may include undefined cause
of the mortality, although all the deaths were investigated
by medical chart or death certificate. Development of
coronary artery disease and corresponding treatment during
the follow-up may have a substantial impact on survival.
CONCLUSIONS
The cryopreserved aortic allograft was durable for more
than 15 years after implantation. The subcoronary implan-
tation technique was more durable than the full-root tech-
nique, whereas the full-root technique was useful in
treating active infective endocarditis. Patients with multiple
cardiovascular risk factors or history of repeated blood
transfusions may be less optimal candidates for allograft
implantation, whereas encouraging patients to embrace a
healthy lifestyle with appropriate medical care may prolong
allograft durability. Reintervention for the implanted aortic
allograft can provide favorable outcomes by using an
appropriate surgical approach and technical proficiency.
Completion of the study allows an opportunity to reflect.
At The Prince Charles Hospital, allograft use is now
minimal except in special circumstances because of the
technical difficulty associated with the reoperation. The
current indications for allograft implantation are (1) endo-
carditis and (2) the young patient with a poor prospect for
follow-up, given that the allograft’s structural deterioration
is slowly progressive; in both circumstances, the preference
is for subcoronary implantation rather than the full-root
technique. The factors associated with structural deteriora-
tion identified in this study provide important implications
in the use of the biological valve prosthesis for valve
disease, including transcatheter aortic valve replacement.
The authors thank Drs Mark O’Brien, Greg Stafford, Michael
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FIGURE E1. Freedom from allograft infection was estimated using the
Kaplan–Meier method. The study cohorts were divided according to
preoperative native aortic valve pathologies, active infective endocarditis,
treated infective endocarditis, and no history of infective endocarditis.
TABLE E2. Potential risk factors of survival post-allograft
implantation: Single variable analyses
Variables P value
Background
Year of surgery <.001
Age (y) <.001
Gender .707
BMI>35 kg/m2 .110
Smoking history .002
History of blood transfusion .132
Hypertension <.001
Dyslipidemia .102
Diabetes .001
Renal failure (preoperative serum creatinine>150 mmol/L) <.001
Preoperative information
AI (nil or trivial, mild, moderate, severe) .019
Surgical indication (AS, AI, mixed, aneurysm) .367
Cause (degenerative, congenital, rheumatic) <.001
Endocarditis (none, active, treated) .92
Preoperative LVEF<40% .001
Previous intervention (none, allograft, prosthesis, valve repair,
coarctation)
.898
NYHA functional class III or IV <.001
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DTABLE E1. Risk factors of in-hospital mortality post-allograft
implantation
HR 95% CI P value
Year of surgery 1.00 0.92-1.07 .898
Elderly age (y) 1.06 1.02-1.11 .004
Female gender 2.16 0.70-6.62 .178
Preoperative renal failure* 6.90 2.08-22.7 .002
Any smoking history 3.21 1.16-8.85 .025
NYHA functional class III of IV 7.04 2.28-21.7 .001
Donor annular size (mm) 0.87 0.64-1.16 .335
Concomitant mitral valve surgery 0.68 0.16-2.10 .410
CI, Confidence interval; HR, hazard ratio; NYHA, New York Heart Association.
*Renal failure refers to serum creatinine>150 mmol/L.
Operative and perioperative characteristics
Implantation technique (subcoronary, full-root, inclusion-
cylinder)
.001
Concomitant coronary artery bypass graft <.001
Concomitant mitral valve <.001
Concomitant ascending aorta .022
Native aortic annulus (mm) .127
Native aortic annulus>28 mm .006
Native aortic annulus<21 mm .187
Nil aortic annular calcification .006
Severe aortic annular calcification .972
Donor information
Donor age (y) .138
Donor age>50 y .771
Donor annulus (mm) .058
Gender mismatch .249
Blood group mismatch .212
Rh antigen mismatch .455
Annular size mismatch (>5 mm) .152
AI, Aortic insufficiency; AS, aortic stenosis; BMI, body mass index; LVEF, left ven-
tricular ejection fraction; NYHA, New York Heart Association.
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TABLEE3. Potential risk factors of structural allograft deterioration:
Single variable analyses
Variables P value
Background
Age (y) <.001
Gender .027
BMI>35 kg/m2 .013
Smoking history .701
History of blood transfusion .002
Hypertension .402
Dyslipidemia .313
Diabetes .867
Renal failure (preoperative serum creatinine>150 mmol/L) .641
Preoperative information
AI (nil or trivial, mild, moderate, severe) <.001
Surgical indication (AS, AI, mixed, aneurysm) <.001
Cause (degenerative, congenital, rheumatic) .040
Endocarditis (none, active, treated) .199
Preoperative LVEF<40% .299
Previous intervention (none, allograft, prosthesis, valve repair,
coarctation)
.022
NYHA functional class III or IV .620
Operative and perioperative characteristics
Implantation technique (subcoronary, full-root, inclusion-
cylinder)
<.001
Concomitant coronary artery bypass graft .045
Concomitant mitral valve .303
Concomitant ascending aorta .001
Native aortic annulus (mm) .286
Native aortic annulus>28 mm .276
Native aortic annulus<21 mm .670
Nil aortic annular calcification <.001
Severe aortic annular calcification .175
Donor information
Donor age (y) .004
Donor age>50 y .001
Donor annulus (mm) .002
Gender mismatch .910
Blood group mismatch .312
Rh antigen mismatch .780
Annular size mismatch (>5 mm) .395
AI, Aortic insufficiency; AS, aortic stenosis; BMI, body mass index; LVEF, left ven-
tricular ejection fraction; NYHA, New York Heart Association.
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